20100135979 | STABILIZED SUSPENSION - A stabilized, colloidal free radical reduced aqueous suspension containing a complex of amorphous Hyaluronic acid (HA) with a mean molecular weight (mean MW) in the range of 80 to 400 kDa and amorphous protein drug, such as insulin, glucagon-like peptide 1 (GLP1), human growth hormone (hGH), erythropoietin (EPO) and super oxide dismutase (SOD), and an excess amount of HA, for example a HA with a mean MW of 6-15 kDa, to minimize the water-content, is described. The composition may additionally comprise HA with a mean MW in the range between 1 and 8 kDa when it is in lyophilized free-flowing powder form. Further, a pharmaceutical composition comprising the suspension and a method of producing the suspension including production of amorphous hyaluronic acid and amorphous protein, are disclosed. The pharmaceutical composition is intended for oral as well as parenteral administration. | 06-03-2010 |